Cyprotex PLC Partnership in the EC funded EU-ToxRisk consortium
October 13 2015 - 2:00AM
RNS Non-Regulatory
TIDMCRX
Cyprotex PLC
13 October 2015
Cyprotex PLC
("Cyprotex" or "the Company")
Partnership in the EC funded EU-ToxRisk consortium
Cyprotex PLC (AIM:CRX), a specialist ADME-Tox and Bioscience
Contract Research Organisation, today announces that it will form
part of the EU-ToxRisk consortium; a project funded by the European
Commission to work on the integration of new concepts for
regulatory chemical safety assessment. A total of 39 partners are
involved in the consortium ranging from industry, academia,
research institutes, contract research organisations and regulatory
bodies.
The EU-ToxRisk project will start in January 2016 and run for 6
years. The project is funded by the European Commission through its
Horizon 2020 programme for Research and Innovation and has a total
value to all partners of EUR30 million over 6 years. The award to
Cyprotex is anticipated to be worth approximately EUR1.0 million
over the 6 year period. The aim of the project is to develop new
cutting-edge human relevant in vitro non-animal methods and in
silico computational technologies for the early assessment of
potential toxicity in humans. The ultimate goal is to provide the
basis of future regulatory chemical safety testing using
animal-free approaches for hazard and risk assessment. Cyprotex
plays a major role in the delivery of absorption, distribution,
metabolism and excretion (ADME) data to the consortium and will
also be involved in validation of some of the newly developed
toxicity models.
Anthony Baxter PhD, Chief Executive Officer of Cyprotex,
comments, 'We are delighted to be part of the EU-ToxRisk
consortium. The project is very much in line with the ethos of the
Company where we have been developing in vitro and in silico
methods for predicting human outcome for over 16 years. Animal
testing is notoriously poor at predicting human safety for certain
types of toxicity and awareness of the ethical issues associated
with animal testing is growing rapidly. Developing more
sophisticated human relevant models will help in addressing these
issues, as well as improving the speed and efficiently of
screening.'
For more information, the official press release issued by the
consortium can be found below:
http://www.rns-pdf.londonstockexchange.com/rns/0271C_-2015-10-12.pdf
Alternatively this is available at the following link:
http://science.leidenuniv.nl/index.php/research/projects/eu-toxrisk
For further information:
Cyprotex PLC Tel: +44 (0) 1625
505 100
Dr Anthony Baxter, Chief Executive ir@cyprotex.com
Officer www.cyprotex.com
John Dootson, Chief Financial
Officer
Mark Warburton, Chief Operating
Officer and Legal Counsel
N+1 Singer (Nomad and broker to Tel: +44 (0)20 7496
Cyprotex) 3000
Shaun Dobson shaun.dobson@n1singer.com
Jen Boorer jennifer.boorer@n1singer.com
www.n1singer.com
Notes to Editors
About Cyprotex PLC
Cyprotex is listed on the AIM market of the London Stock
Exchange (CRX). It has sites at Macclesfield and Alderley Park,
both of which are near Manchester in the UK, and at Watertown, MA
and Kalamazoo, MI in the US. The Company was established in 1999
and works with more than 1200 partners within the pharmaceutical
and biotech industry, cosmetics and personal care industry and the
chemical industry. Cyprotex acquired Apredica and the assets of
Cellumen Inc. in August 2010 and the combined business provides
support for a wide range of experimental and computational ADME-Tox
and PK services. The acquisition of the assets and business of
CeeTox in January 2014 has enabled Cyprotex to expand its range of
services to target the personal care, cosmetics and chemical
industries. In 2015, Cyprotex launched its new bioscience division
to expand its capabilities into phenotypic and target based
screening. The Company's core capabilities include high quality in
vitro ADME screening services, mechanistic toxicology and high
content toxicology screening services, including our proprietary
CellCiphr(R) toxicity prediction technology, bioscience services,
predictive modelling using PBPK, including Cloe(R) PK for in vivo
PK prediction, and a range of skin, ocular and endocrine disruption
services. For more information, see www.cyprotex.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAPKBDDOBDDFKD
(END) Dow Jones Newswires
October 13, 2015 02:00 ET (06:00 GMT)
Cyprotex (LSE:CRX)
Historical Stock Chart
From Apr 2024 to May 2024
Cyprotex (LSE:CRX)
Historical Stock Chart
From May 2023 to May 2024